



RECEIVED

APR 15 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Application of:

Beach, David.

APR 03 2002

Attorney Docket No. GPCI-P10-019

Serial No: 09/699,580

TECH CENTER 1600/2900

Art Unit: 1633

Filed: October 30, 2000

Examiner: N/A

For: Novel CDC25 Genes, Encoded Products
and Uses Thereof

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

3/22/02

Date of Signature
and of Mail Deposit

Anna P. Lucey
Anna P. Lucey

Assistant Commissioner for Patents
United State Patent and Trademark Office
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT IN COMPLIANCE WITH 37

CFR §§ 1.97(b) and 1.98(d)

Submitted herewith on Form PTO-1449 is a list of publications that applicants and their agents/attorneys have identified during the preparation of this application. In accordance with CFR § 1.98 (d), applicants respectfully submit that **no copy** of any patent, publication, or other information listed on the enclosed Form PTO 1449 is needed because the citations were made in prior application U.S.S.N. 08/428,415, filed April 24, 1995 which is relied upon for an earlier filing date under 35 U.S.C. 120.

This Information Disclosure Statement is being filed before the mailing of the first office action on the merits; therefore, no fee is due.


Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits, and as such applicants believe no fees are due at this time. However, should any fees need to be paid in connection with this submission, the Commissioner is hereby authorized to credit any overpayment or charge any deficiency to/from **Deposit Account No. 18-1945**, under Order No. GPCI-P10-019.

Respectfully submitted,
Ropes & Gray

By: 
David P. Halstead, Ph.D.
Reg. No. 44,735

Dated:
Customer No. 28120
Ropes & Gray
Patent Group
One International Place
Boston, MA 02110-2624

Form PTO-1449		Docket Number (Optional) GPCI-P10-019		Application Number 09/699,580	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)					
Applicant Beach, David		Filing Date October 30, 2000		Group Art Unit 1633	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE IF APPROPRIATE
	AA	5,441,880	8/15/94	Beach	
	AB	5,294,538	3/15/94	Beach	
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Translation YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.)					
AC	Baratte et al. Screening for Antimitotic Compounds Using the cdc25 Tyrosine Phosphatase, an Activator of the Mitosis-inducing p34cdc2/cyclinBcdc13 Protein Kinase. <i>Anticancer Research</i> 12, 873-880 (1992).				
AD	Camonis et al. Characterization, Cloning and Sequence Analysis of the CDC25 Gene which Controls the Cyclic AMP Level of <i>Saccharomyces Cerevisiae</i> . <i>EMBO J.</i> 5, 375-380 (1986).				
AE	Daniel, The CDC25 "Start" Gene of <i>Saccharomyces Cerevisiae</i> : Sequencing of the Active C-terminal Fragment and Regional Homologies with Rhodopsin and Cytochrome P450. <i>Curr. Genet.</i> 10, 879-885 (1986).				
AF	Daniel et al. Clones from Two Different Genomic Regions Complement the cdc25 Start Mutation of <i>Saccharomyces</i> . <i>Curr. Genet.</i> 10, 643-646 (1986).				
AG	Dunphy et al. The cdc25 Protein Contains an Intrinsic Phosphatase Activity. <i>Cell</i> 67, 189-196 (1991).				
AH	Galaktionov et al. Specific Activation of cdc25 Tyrosine Phosphatases by B-Type Cyclins: Evidence for Multiple Roles of Mitotic Cyclins. <i>Cell</i> 67, 1181-1194 (1991).				
AI	Gautier et al. Cdc 25 is a Specific Tyrosine Phosphatase that Directly Activates p34cdc2. <i>Cell</i> 67, 197-211 (1991).				
AJ	Gould et al. Complementation of the Mitotic Activator, p80cdc25, by a Human Protein-Tyrosine Phosphatase. <i>Science</i> 250, 1573-1576 (1990).				
AK	Jessus et al. Oscillation of MPF is Accompanied by Periodic Association between cdc25 and cdc2-Cyclin B. <i>Cell</i> 68, 323-332 (1992).				
AL	Jimenez et al. Complementation of Fission Yeast cdc2ts and cdc25ts Mutants Identifies Two Cell Cycle Genes from <i>Drosophila</i> : a cdc25 Homologue and String. <i>EMBO J.</i> 9, 3565-3571 (1990).				
AM	Kakizuka et al. A Mouse cdc25 Homolog is Differentially and Developmentally Expressed. <i>Genes & Development</i> 6, 578-590 (1992).				

Form PTO-1449		Docket Number (Optional)		Application Number	
INFORMATION DISCLOSURE CITATION		GPCI-P10-019		09/699,580	
IN AN APPLICATION		Applicant		APR 15 2002	
(Use several sheets if necessary)		Beach, David		TECH CENTER 1600/2900	
		Filing Date		Group Art Unit	
		October 30, 2000		1633	
AN	Kumagai et al. The cdc25 Protein Controls Tyrosine Dephosphorylation of the cdc2 Protein in a Cell-Free System. <i>Cell</i> 64, 903-914 (1991).				
AO	Lee et al. Cdc25 Encodes a Protein Phosphatase that Dephosphorylates p34cdc2. <i>Mol. Biol.</i> 3, 73-84 (1992).				
AP	Lerner. Tapping the Immunological Repertoire. <i>Nature</i> 299 (14 October 1982).				
AQ	Millar et al. The cdc25 M-Phase Inducer: An Unconventional Protein Phosphatase. <i>Cell</i> 68, 407-410 (1992).				
AR	Millar et al. P55cdc25 is a Nuclear Protein Required for the Initiation of Mitosis in Human Cells. <i>PNAS</i> 88, 10500-10504 (1991).				
AS	Millar et al. P80cdc25 Mitotic Inducer is the Tyrosine Phosphatase that Activates p34cdc2 Kinase in Fission Yeast. <i>EMBO J.</i> 10, 4301-4309 (1991).				
AT	Moreno et al. Clues to Action of cdc25 Protein. <i>Nature</i> 351, 194 (1991).				
AU	Nagata et al. An additional Homolog of the Fission Yeast cdc25+ Gene Occurs in Humans and is Highly Expressed in Some Cancer Cells. <i>New Biologist</i> 3, 959-968 (1991).				
AV	Ogden et al. Isolation of a Novel Type of Mutation in the Mitotic Control of <i>Schizosaccharomyces Pombe</i> whose Phenotypic Expression is Dependent on the Genetic Background and Nutritional Environment. <i>Curr. Genet.</i> 10, 509-514 (1986).				
AW	Ohno et al. A Yeast Gene Coding for a Putative Protein Kinase Homologous to cdc25 Suppressing Protein Kinase. <i>FEBS</i> 222, 279-285 (1987).				
AX	Osmani et al. Parallel Activation of the NIMA and p34cdc2 Cell Cycle-Regulated Protein Kinases is Required to Initiate Mitosis in <i>A. Nidulans</i> . <i>Cell</i> 67, 283-291 (1991).				
AY	Russell et al. Cdc25+ Functions as an Inducer in the Mitotic Control of Fission Yeast. <i>Cell</i> 45, 145-153 (1986).				
AZ	Sadhu et al. Human Homolog of Fission Yeast cdc25 Mitotic Inducer is Predominantly Expressed in G2. <i>PNAS</i> 87, 5139-5143 (1990).				
BA	Strausfeld et al. Dephosphorylation and Activation of a p34cdc2/cyclin B Complex in vitro by Human CDC25 Protein. <i>Nature</i> 351, 242-245 (1991).				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE